ALBT Key Statistics, Chart & Performance
The current stock price of ALBT is 1.2 USD. In the past month the price decreased by -9.77%. In the past year, price decreased by -67.21%.
ALBT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LB | LANDBRIDGE CO LLC-A | 36.83 | 3.78B | ||
| KW | KENNEDY-WILSON HOLDINGS INC | N/A | 1.33B | ||
| TCI | TRANSCONTINENTAL REALTY INV | 90.18 | 506.48M | ||
| FRPH | FRP HOLDINGS INC | 67.03 | 435.74M | ||
| MLP | MAUI LAND & PINEAPPLE CO | N/A | 334.40M | ||
| ARL | AMERICAN REALTY INVESTORS IN | 44.61 | 259.37M | ||
| OZ | BELPOINTE PREP LLC- CLASS A | N/A | 252.97M | ||
| SEG | SEAPORT ENTERTAINMENT GROUP | N/A | 251.87M | ||
| SRG | SERITAGE GROWTH PROP- A | N/A | 183.04M | ||
| LPA | LOGISTIC PROPERTIES OF THE A | 12.41 | 86.05M | ||
| MAYS | MAYS (J.W.) INC | N/A | 80.68M | ||
| INTG | INTERGROUP CORP | N/A | 61.04M |
Related stock screener links
About ALBT
Company Profile
Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The firm is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
Company Info
AVALON GLOBOCARE CORP
4400 Route 9, Suite 3100
Freehold NEW JERSEY US
Employees: 5
Phone: 17327804400
AVALON GLOBOCARE CORP / ALBT FAQ
Can you describe the business of AVALON GLOBOCARE CORP?
Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The firm is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
What is the current price of ALBT stock?
The current stock price of ALBT is 1.2 USD. The price decreased by -4.76% in the last trading session.
Does ALBT stock pay dividends?
ALBT does not pay a dividend.
What is the ChartMill rating of AVALON GLOBOCARE CORP stock?
ALBT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ALBT stock?
ALBT stock is listed on the Nasdaq exchange.
Is AVALON GLOBOCARE CORP (ALBT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALBT.
Can you provide the ownership details for ALBT stock?
You can find the ownership structure of AVALON GLOBOCARE CORP (ALBT) on the Ownership tab.
ALBT Technical Analysis
ALBT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALBT. ALBT may be in some trouble as it scores bad on both profitability and health.
ALBT Financial Highlights
Over the last trailing twelve months ALBT reported a non-GAAP Earnings per Share(EPS) of -9.75. The EPS increased by 50.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -205.48% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |